There is exciting news for patients who suffer from Alopecia Univeralis (UA). A Yale Doctor has prescribed a completely bald man suffering from alopecia universalis a drug called Xeiljanz, which is used to treat autoimmune disorders such as rheumatoid arthritis, in order to treat his hairlessness.
What is Alopecia Universalis?
Alopecia Universalis, a severe variation of Alopecia Areata (AA), is a skin condition that causes rapid hair loss not only on the scalp but in the entire body. It is a rare condition with an incidence of about one in every two hundred thousand people.
This report from Dr. Brett King explains how the 25-Year-Old Hairless patient was able to completely regrow the hair on his scalp, eyebrows, and eyelashes in eight months after taking Xeilanz.
What is Xeiljanz?
Xeiljanz is an inhibitor of the enzyme janus kinase 3. That means the medication can interfere with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA transcription. The final effect of this medication that makes it useful for inflammatory diseases and in this case alopecia universalis is its anti-inflammatory effect.
What does it mean people with common baldness?
Although Xeiljanz treatment seems very promising for patients with alopecia Areata and Universalis, it is not likely to impact the majority of people suffering from Androgenetic Alopeica (male patterned baldness). The experimental treatment of Alopecia Universalis with immunomodulators is not a new concept, and more information is needed from clinical trials to see if the Xeiljanz could be used as a hair
loss treatment for male patterned baldness.
The post Novel Treatment for Alopecia Universalis appeared first on Hair Restoration Blog.